<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33784285</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>29</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2444-054X</ISSN><JournalIssue CitedMedium="Internet"><Volume>89</Volume><Issue>2</Issue><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>Cirugia y cirujanos</Title><ISOAbbreviation>Cir Cir</ISOAbbreviation></Journal><ArticleTitle>Risk factors associated with diabetic neuropathy in Mexican patients.</ArticleTitle><Pagination><StartPage>189</StartPage><EndPage>199</EndPage><MedlinePgn>189-199</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.24875/CIRU.20000243</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Diabetic neuropathy (DN) is one of the most common complications of type 2 diabetes (T2D) and is a leading cause of lower limb amputation. The aim of the present study was to evaluate the risk factors contributing to DN in Mexican patients through the comparison of T2D patients with and without DN.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">This cross-sectional study consisted of 509 subjects from Mexico who were classified as with DN and without DN. DN was assessed according to Douleur Neuropathique 4 questionnaire. Logistic regression analysis was performed to analyze risk factors contributing to DN.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The prevalence of DN in the studied population was 28.3%. The risk factors associated with DN were T2D duration (odds ratio [OR]: 2.51; 95% confidence interval [CI] 1.36-4.65), glycemic exposure index (OR: 1.82; 95% CI 1.01-3.64), low- and high-density lipoprotein levels (OR: 1.53; 95% CI 1.02-2.31), metformin treatment (OR: 2.08; 95% CI 1.11-3.91), diabetic retinopathy (OR: 1.65; 95% CI 1.07-2.54), and smoking (OR: 1.51; 95% CI 1.00-2.26).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Therefore, the early identification of risk factors for DN development in Mexican population would allow implementing personalized strategies to improve the overall T2D patients' quality of life and reduce healthcare costs in our country.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2021 Permanyer.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>S&#xe1;nchez-Pozos</LastName><ForeName>Katy</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Endocrinology, Hospital Ju&#xe1;rez de M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monroy-Escutia</LastName><ForeName>Jazm&#xed;n</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Endocrinology, Hospital Ju&#xe1;rez de M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jaimes-Santoyo</LastName><ForeName>Joel</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Endocrinology, Hospital Ju&#xe1;rez de M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Granados-Silvestre</LastName><ForeName>Ma de Los &#xc1;ngeles</ForeName><Initials>ML&#xc1;</Initials><AffiliationInfo><Affiliation>Faculty of Chemistry, Universidad Nacional Aut&#xf3;noma de M&#xe9;xico, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Menjivar</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Faculty of Chemistry, Universidad Nacional Aut&#xf3;noma de M&#xe9;xico, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ortiz-L&#xf3;pez</LastName><ForeName>Ma Guadalupe</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Endocrinology, Hospital Ju&#xe1;rez de M&#xe9;xico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Factores de riesgo asociados a neuropat&#xed;a diab&#xe9;tica en pacientes mexicanos.</VernacularTitle></Article><MedlineJournalInfo><Country>Mexico</Country><MedlineTA>Cir Cir</MedlineTA><NlmUniqueID>0372736</NlmUniqueID><ISSNLinking>0009-7411</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="Y">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003929" MajorTopicYN="Y">Diabetic Neuropathies</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008800" MajorTopicYN="N" Type="Geographic">Mexico</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText Label="ANTECEDENTES" NlmCategory="BACKGROUND">La neuropat&#xed;a diab&#xe9;tica (ND) es una de las complicaciones m&#xe1;s comunes de la diabetes tipo 2 (DT2). &#xad;.</AbstractText><AbstractText Label="OBJETIVO" NlmCategory="OBJECTIVE">Investigar los factores de riesgo que contribuyen al desarrollo de ND en poblaci&#xf3;n mexicana con DT2, comparando pacientes diab&#xe9;ticos con y sin ND.</AbstractText><AbstractText Label="M&#xc9;TODO" NlmCategory="UNASSIGNED">Estudio transversal con 509 pacientes mexicanos con DT2, clasificados en dos grupos, con y sin ND. La ND fue diagnosticada con el cuestionario DN4. La identificaci&#xf3;n de los factores de riesgo de ND se realiz&#xf3; mediante un an&#xe1;lisis de regresi&#xf3;n log&#xed;stica.</AbstractText><AbstractText Label="RESULTADOS" NlmCategory="RESULTS">La prevalencia de ND en la poblaci&#xf3;n de estudio fue del 28.3%. Los factores de riesgo asociados a ND fueron la duraci&#xf3;n de la DT2 (odds ratio [OR]: 2.51; intervalo de confianza del 95% [IC 95%]: 1.36-4.65), el &#xed;ndice gluc&#xe9;mico (OR: 1.82; IC 95%: 1.01-3.64), las concentraciones bajas de colesterol unido a lipoprote&#xed;nas de alta densidad (OR: 1.53; IC 95%: 1.02-2.31), el tratamiento con metformina (OR: 2.08; IC 95%: 1.11-3.91), la retinopat&#xed;a diab&#xe9;tica (OR: 1.65; IC 95%: 1.07-2.54) y el tabaquismo (OR: 1.51; IC 95%: 1.00-2.26).</AbstractText><AbstractText Label="CONCLUSIONES" NlmCategory="CONCLUSIONS">La identificaci&#xf3;n temprana de los factores de riesgo para el desarrollo de ND en poblaci&#xf3;n mexicana permitir&#xe1; implementar estrategias personalizadas para mejorar la calidad de vida de los pacientes con DT2 y disminuir el gasto del sector salud originado por esta complicaci&#xf3;n.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2021 Permanyer.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Complicaciones de diabetes</Keyword><Keyword MajorTopicYN="N">Diabetes complications</Keyword><Keyword MajorTopicYN="N">Diabetes tipo 2</Keyword><Keyword MajorTopicYN="N">Diabetic neuropathy</Keyword><Keyword MajorTopicYN="N">Glycemic index</Keyword><Keyword MajorTopicYN="N">Insulin resistance</Keyword><Keyword MajorTopicYN="N">Neuropat&#xed;a diab&#xe9;tica</Keyword><Keyword MajorTopicYN="N">Resistencia a la insulina</Keyword><Keyword MajorTopicYN="N">Type 2 diabetes</Keyword><Keyword MajorTopicYN="N">&#xcd;ndice gluc&#xe9;mico</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>30</Day><Hour>17</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33784285</ArticleId><ArticleId IdType="doi">10.24875/CIRU.20000243</ArticleId><ArticleId IdType="pii">j89/2/189</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31859889</PMID><DateCompleted><Year>2020</Year><Month>01</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>01</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">0717-6163</ISSN><JournalIssue CitedMedium="Internet"><Volume>147</Volume><Issue>5</Issue><PubDate><Year>2019</Year><Month>May</Month></PubDate></JournalIssue><Title>Revista medica de Chile</Title><ISOAbbreviation>Rev Med Chil</ISOAbbreviation></Journal><ArticleTitle>[Gestational diabetes adherence to treatment and metabolic control].</ArticleTitle><Pagination><StartPage>574</StartPage><EndPage>578</EndPage><MedlinePgn>574-578</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4067/S0034-98872019000500574</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0034-98872019000500574</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Adherence to treatment is a large obstacle in the management of chronic diseases.</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To evaluate therapeutic adherence and its relationship with glycemic control in patients with gestational diabetes using two types of treatment.</AbstractText><AbstractText Label="MATERIAL AND METHODS" NlmCategory="METHODS">The Measurement of Treatment Adherence (MAT) questionnaire was applied to 93 patients with gestational diabetes. Fifty-two used metformin 41 were treated with insulin. Obstetric and socio-demographic data were collected.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A higher therapeutic adherence was associated with a better glycemic control. Women with a higher education level had a better adherence to treatment. The adherence and metabolic control were higher in women treated with metformin.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Therapeutic adherence is an important factor for adequate glycemic control.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ch&#xe1;vez-Garc&#xed;a</LastName><ForeName>Linet</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Departamento de Ginecolog&#xed;a y Obstetricia, Hospital General Regional n&#xfa;mero uno, Instituto Mexicano del Seguro Social, Sonora, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valle-Leal</LastName><ForeName>Jaime Guadalupe</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>Departamento de Pediatr&#xed;a, Hospital General Regional n&#xfa;mero uno, Instituto Mexicano del Seguro Social, Sonora, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jim&#xe9;nez-Mapula</LastName><ForeName>Cindy</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Departamento de Ginecolog&#xed;a y Obstetricia, Hospital General Regional n&#xfa;mero uno, Instituto Mexicano del Seguro Social, Sonora, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quintero-Medrano</LastName><ForeName>Samantha Melissa</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Departamento de Ginecolog&#xed;a y Obstetricia, Hospital General Regional n&#xfa;mero uno, Instituto Mexicano del Seguro Social, Sonora, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xf3;pez-Villegas</LastName><ForeName>Miriam Nayeli</ForeName><Initials>MN</Initials><AffiliationInfo><Affiliation>Departamento de Ginecolog&#xed;a y Obstetricia, Hospital General Regional n&#xfa;mero uno, Instituto Mexicano del Seguro Social, Sonora, M&#xe9;xico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Adherencia terap&#xe9;utica y control gluc&#xe9;mico en pacientes con diabetes gestacional bajo dos esquemas de tratamiento.</VernacularTitle></Article><MedlineJournalInfo><Country>Chile</Country><MedlineTA>Rev Med Chil</MedlineTA><NlmUniqueID>0404312</NlmUniqueID><ISSNLinking>0034-9887</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007328">Insulin</NameOfSubstance></Chemical><Chemical><RegistryNumber>9100L32L2N</RegistryNumber><NameOfSubstance UI="D008687">Metformin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016640" MajorTopicYN="N">Diabetes, Gestational</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004522" MajorTopicYN="N">Educational Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005865" MajorTopicYN="N">Gestational Age</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007004" MajorTopicYN="N">Hypoglycemic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007328" MajorTopicYN="N">Insulin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008687" MajorTopicYN="N">Metformin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000099059" MajorTopicYN="Y">Assessment of Medication Adherence</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>2</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>4</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>12</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>12</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>1</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31859889</ArticleId><ArticleId IdType="doi">10.4067/S0034-98872019000500574</ArticleId><ArticleId IdType="pii">S0034-98872019000500574</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31399388</PMID><DateCompleted><Year>2020</Year><Month>12</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1578-8865</ISSN><JournalIssue CitedMedium="Internet"><Volume>46</Volume><Issue>2</Issue><PubDate><Year>2020</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Semergen</Title><ISOAbbreviation>Semergen</ISOAbbreviation></Journal><ArticleTitle>[Blood glucose control and cardiovascular risk factors in type 2 diabetic patients with cardiovascular disease in Spain, and its treatment pattern, according to gender: CODICE study].</ArticleTitle><Pagination><StartPage>125</StartPage><EndPage>135</EndPage><MedlinePgn>125-135</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.semerg.2019.05.005</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1138-3593(19)30203-5</ELocationID><Abstract><AbstractText Label="INTRODUCTION AND OBJECTIVES" NlmCategory="OBJECTIVE">With the implementation of the Strategy of Health Promotion and Prevention in Spain, the scenario reflected in previous studies of low control of cardiovascular risk factors (CVRF) in patients with type 2 diabetes (DM2) and cardiovascular disease (CVD) can be modified. This study intends to determine the level of blood glucose control and other CVRF in patients with DM2 and CVD currently seen in clinics in Spain, as well as the pattern of antidiabetic treatment, and differences according to gender.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">An epidemiological, observational, cross-sectional, nationwide study was conducted in patients of both genders diagnosed with DM2 and established CVD.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The study included 3,143 patients with a mean age 69.0&#xb1;10 years. The mean HbA1c was 7.4&#xb1;1.1% in females vs 7.3&#xb1;1.2% in males (P&lt;.05) and systolic blood pressure was 137&#xb1;15.0mmHg in females vs 135.6&#xb1;14.7mmHg in males (P&lt;.05). The mean LDL-cholesterol was 101.5&#xb1;38.1mg/dl in females vs 91.1&#xb1;37.5mg/dl in males; P&lt;.001) and the mean body mass index (30.7&#xb1;5.4kg/m<sup>2</sup> in females vs 29.6&#xb1;4.5kg/m<sup>2</sup> in males; P&lt;.001). The most used treatments were metformin (68.1%) and/or DPP4 inhibitors (53.7%), with no differences between genders.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The level of blood glucose control of DM2 patients with CVD in Spain can be improved. The treatment profile does not conform to the recommendations of clinical practice guidelines in general. The differences in the control of CVRF are worse in women for lipids and obesity.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 Sociedad Espa&#xf1;ola de M&#xe9;dicos de Atenci&#xf3;n Primaria (SEMERGEN). Publicado por Elsevier Espa&#xf1;a, S.L.U. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>G&#xf3;mez Garc&#xed;a</LastName><ForeName>M C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Unidad de Gesti&#xf3;n Cl&#xed;nica V&#xe9;lez-Norte, V&#xe9;lez-M&#xe1;laga, M&#xe1;laga, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Franch-Nadal</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Centro de Salud de Raval Sud, Barcelona, Espa&#xf1;a. Electronic address: josep.franch@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Millaruelo Trillo</LastName><ForeName>J M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Centro de Salud Torrero La Paz, Zaragoza, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cos-Claramunt</LastName><ForeName>F X</ForeName><Initials>FX</Initials><AffiliationInfo><Affiliation>Centro de Salut Sant Marti de Proven&#xe7;als, Barcelona, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Avila Lachica</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Unidad de Gesti&#xf3;n Cl&#xed;nica V&#xe9;lez-Norte, V&#xe9;lez-M&#xe1;laga, M&#xe1;laga, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buil Cosiales</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Centro de Salud Azpilaga&#xf1;a, Pamplona, Navarra, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><VernacularTitle>Control gluc&#xe9;mico y de los factores de riesgo cardiovascular en los pacientes con diabetes tipo 2 con enfermedad cardiovascular en Espa&#xf1;a, y su patr&#xf3;n de tratamiento, en funci&#xf3;n del g&#xe9;nero: Estudio CODICE.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2019</Year><Month>08</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Semergen</MedlineTA><NlmUniqueID>9610769</NlmUniqueID><ISSNLinking>1138-3593</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006442">Glycated Hemoglobin A</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008055">Lipids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C517652">hemoglobin A1c protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001794" MajorTopicYN="N">Blood Pressure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006442" MajorTopicYN="N">Glycated Hemoglobin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000085002" MajorTopicYN="Y">Glycemic Control</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000082742" MajorTopicYN="N">Heart Disease Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007004" MajorTopicYN="N">Hypoglycemic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008055" MajorTopicYN="N">Lipids</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009765" MajorTopicYN="N">Obesity</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiovascular risk</Keyword><Keyword MajorTopicYN="N">Control targets</Keyword><Keyword MajorTopicYN="N">Diabetes mellitus tipo 2</Keyword><Keyword MajorTopicYN="N">Diabetes mellitus type 2</Keyword><Keyword MajorTopicYN="N">Gender</Keyword><Keyword MajorTopicYN="N">G&#xe9;nero</Keyword><Keyword MajorTopicYN="N">Objetivos control</Keyword><Keyword MajorTopicYN="N">Riesgo cardiovascular</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>1</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>5</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>5</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31399388</ArticleId><ArticleId IdType="doi">10.1016/j.semerg.2019.05.005</ArticleId><ArticleId IdType="pii">S1138-3593(19)30203-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>